कार्डियोवास्कुलर फार्माकोलॉजी: ओपन एक्सेस

अमूर्त

Eplerenone in Post Myocardial Infarction Patients

Desmond C and Katira R

Background: Eplerenone is a mineralocorticoid receptor antagonist (MRA), which is currently used in patients post myocardial infarction (MI) with symptoms of heart failure and left ventricular systolic dysfunction. NICE guidelines 2013 sets out the use of Eplerenone in a post-MI setting.
Aim: The aim of this guideline review is to analyse recent literature (2013 onwards) to valuate if NICE guideline is still relevant to clinical practice.
Method: Literature search was conducted to find articles from 2013-present, in English, and contained the key words “Eplerenone” and “myocardial infarction” in the subject title.
Results: Seven articles were found. They were read and evaluated to see how Eplerenone effects clinical outcomes in a variety of settings.
Conclusion: The NICE guideline is still relevant in light of evidence from more recently published literature. However further research is suggested to be completed in future to assess the effect of Eplerenone in patients without heart failure post-MI as in REMINDER trial